the effect of febuxostat in sepsis
Phase 3
Recruiting
- Conditions
- sepsis.
- Registration Number
- IRCT20230814059148N1
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Septic patients who are hospitalized in the intensive care unit
Exclusion Criteria
Patients taking Azathioprine, Mercaptopurine, or Methotrexate at the same time
Patients with sensitivity to Febuxostat or Allopurinol or Lactose or any component of the formulation of these drugs
Patients with severe liver failure class C (ALT >3×ULN and total serum bilirubin more than 2×ULN)
Patients with malignancy
Pregnant and lactating women
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Interleukin 6 (IL-6) plasma level. Timepoint: Day 0 (before the start) and day 4 of the study. Method of measurement: ELISA kit for detection of interleukin 6 serum level.
- Secondary Outcome Measures
Name Time Method The state of organ failure in sepsis. Timepoint: Days 0, 3, 7, 10. Method of measurement: Sequential Organ Failure Assessment (SOFA) Score.